Connect with us


Global Budesonide Market Size and Forecast [PDF] 2021-2027 Sandoz, Cosmo Pharmaceuticals, Salix – The Courier



Global Budesonide Market Research Report 2021-2027 , which has been recently added to our vast depository of research report. Our latest published report on Budesonide market is accountable to offer an in-depth investigation and understanding on each of the segment that ultimately pinpoints the key major aspects of the Budesonide industry. Besides this, the Budesonide market report delivers a modern scenarios of the recent and upcoming industry procedures, assessment of new techniques as well as extensive advancement in the product generation.

Access Full Details of Budesonide Market Report 2021:

The Budesonide market report incorporates distinct approaches as well as procedures utilized by the Budesonide market manufacturers in order to generate crucial business decisions. The research study on Budesonide market also depicts some vital components such as production value, Budesonide marketing strategy analysis, distributors or traders of the market and their impact is also mentioned in the Budesonide industry research document. Moreover, the report also reveals the Budesonide market overview, market share, demand/supply ratio, product offerings, import/export data and supply chain analysis.

NOTE: Our reports include the analysis of the impact of COVID-19 on this industry. Our new sample is updated which correspond in new report showing impact of Covid-19 on Industry trends. Also we are offering 20% discount

The study report delivers an exclusive tool for evaluating the Budesonide industry, outlining opportunities, strategic decision-making and supporting growth prospects of the Budesonide market. This report recognizes the rapidly changing competition landscape of the Budesonide industry along with expected CAGR during forecast, growth factors, recent marketing facts which are important to monitor the performance of the Budesonide market and make vital decisions for industry progress and probability.

Do You Have Any Query or Specific Requirement? Ask to Our Industry Expert

Be Sure To Check Out Our Previous Research:

CNC Machines Market Size
Automotive Relays Market Size
Water Treatment Agent Market Size

Major Market Players indulged in this report are:

Cosmo Pharmaceuticals
Chiesi Farmaceutici
Orion Corporation
Synmosa Biopharma
Lunan Better Pharma
Shanghai Sine Promod

Budesonide Market 2021 segments by product types:

Injectable Suspension
Inhalation Powder
Tablet and Capsule

The Application of the World Budesonide Market 2021-2027 as follows:

Respiratory Disease Treatment
Nose Disease Treatment
Inflammatory Bowel Disease Treatment

The Budesonide market research report consists of an elaborated primary research and exclusive analysis of the quantitative and qualitative elements of the Budesonide industry that has been derived by several market professionals and specialists in order to acquire a deeper knowledge of the world Budesonide industry and the whole landscape. The major aim of the report is to focus on current volume and value of the Budesonide market share by regions, by key players, by product type, by consumers and also by unstable market prices.

Checkout FREE Report Sample of Budesonide Market Report 2021-2027 for Better Understanding:

The Budesonide Market report provides upstream and downstream analysis of Budesonide market that covering major raw material used in manufacturing of Budesonide along with detailed manufacturing sources. Budesonide report Detailed raw material price trend analysis along with Budesonide manufacturing cost analysis is also incorporated into the report.

If you are already operated in the Global Budesonide market or keen to be, then this study is perfect guide for you as it will specifically offer a comprehensive outlook of the Budesonide market for you. This allows you to keep your marketing knowledge up to date. If you have a different set of Budesonide market players/ vendors based on the geographical or regional or country needs, then we will assure you to deliver detailed customization of the Budesonide industry as per your requirements.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Down 3.8% After Earnings Miss




Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) dropped 3.8% on Friday after the company announced weaker than expected quarterly earnings. The company traded as low as $49.00 and last traded at $49.04. Approximately 2,777 shares changed hands during trading, a decline of 98% from the average daily volume of 142,041 shares. The stock had previously closed at $51.00.The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.94) by ($0.15). The business had revenue of $20.10 million for the quarter, compared to analysts’ expectations of $25.05 million. Enanta Pharmaceuticals had a negative return on equity of 3.75% and a negative net margin of 29.53%. The company’s revenue for the quarter was down 27.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.30) earnings per share.

A number of brokerages have issued reports on ENTA. JPMorgan Chase & Co. upgraded shares of Enanta Pharmaceuticals from an “underweight” rating to a “neutral” rating and lifted their target price for the stock from $44.00 to $55.00 in a research report on Friday, January 29th. Zacks Investment Research lowered shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, April 27th. Finally, Royal Bank of Canada boosted their price objective on shares of Enanta Pharmaceuticals from $47.00 to $53.00 and gave the company a “sector perform” rating in a research report on Tuesday, February 9th. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. Enanta Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $64.88.


Coinbase – the world’s largest digital currency exchange – just went public.

But this IPO is not the best way to make money in crypto in 2021.

Instead folks need to get in on a handful of valuable crypto plays…

3 of which I just named in a brand new free report, “3 Cryptos to Beat Bitcoin.”

Institutional investors have recently added to or reduced their stakes in the stock. New York State Common Retirement Fund grew its holdings in Enanta Pharmaceuticals by 20.9% in the fourth quarter. New York State Common Retirement Fund now owns 37,898 shares of the biotechnology company’s stock valued at $1,596,000 after purchasing an additional 6,550 shares during the period. Tudor Investment Corp Et Al acquired a new stake in Enanta Pharmaceuticals in the fourth quarter valued at $1,856,000. Virtus ETF Advisers LLC raised its holdings in Enanta Pharmaceuticals by 18.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 14,321 shares of the biotechnology company’s stock valued at $603,000 after acquiring an additional 2,275 shares in the last quarter. Credit Suisse AG raised its holdings in shares of Enanta Pharmaceuticals by 8.3% during the fourth quarter. Credit Suisse AG now owns 37,837 shares of the biotechnology company’s stock worth $1,594,000 after purchasing an additional 2,892 shares during the period. Finally, Rhumbline Advisers raised its holdings in shares of Enanta Pharmaceuticals by 9.6% during the fourth quarter. Rhumbline Advisers now owns 65,257 shares of the biotechnology company’s stock worth $2,747,000 after purchasing an additional 5,698 shares during the period. Hedge funds and other institutional investors own 90.78% of the company’s stock.

The company has a market capitalization of $988.43 million, a price-to-earnings ratio of -28.02 and a beta of 0.54. The stock’s fifty day simple moving average is $50.52 and its two-hundred day simple moving average is $47.52.

About Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus.

Featured Story: What is a front-end load?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: Why Invest in Dividend Kings

7 Hotel Stocks Just Waiting For the Vaccine

Like any group of stocks related to travel and tourism, hotel stocks saw a steep drop in share prices in 2020. The leisure and hospitality sector that once had 15 million employees has lost 4 million jobs since February.

Many major cities will be feeling the ripple effects of the Covid-19 pandemic for years. However, there is ample evidence that shows the pandemic may be coming to an end. The number of new cases is dropping. The number of those getting vaccinated is rising. And even in the cities with the most restrictive mitigation measures, the slow process of reopening is beginning.

All of this can’t come fast enough for individuals who rely on the travel and tourism industry for their livelihood. Hotel chains had at least some revenue coming in the door. And when earnings season concludes, the more budget-friendly hotel chains may realize revenue that is 75% of its 2019 numbers. But that is not enough to bring the hotels to anywhere near full employment. Particularly with hotels that have bars and restaurants that have remained closed or open at limited capacity.

Many economists are optimistic that travel may begin to look more normal by the summer of this year. And the global economy may deliver 6.4% GDP growth this year. With that in mind, the hotel chains with the best fundamentals and the broadest footprint will be in the best position as the economy reopens.

View the “7 Hotel Stocks Just Waiting For the Vaccine”.

Continue Reading


BioCryst Pharmaceuticals Stock –




The stock of BioCryst Pharmaceuticals (NAS:BCRX, 30-year Financials) shows every sign of being significantly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus’ estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $13.12 per share and the market cap of $2.3 billion, BioCryst Pharmaceuticals stock is estimated to be significantly overvalued. GF Value for BioCryst Pharmaceuticals is shown in the chart below.

BioCryst Pharmaceuticals GF Value Chart

Because BioCryst Pharmaceuticals is significantly overvalued, the long-term return of its stock is likely to be much lower than its future business growth.

Link: These companies may deliever higher future returns at reduced risk.

It is always important to check the financial strength of a company before buying its stock. Investing in companies with poor financial strength have a higher risk of permanent loss. Looking at the cash-to-debt ratio and interest coverage is a great way to understand the financial strength of a company. BioCryst Pharmaceuticals has a cash-to-debt ratio of 1.08, which is worse than 83% of the companies in Biotechnology industry. The overall financial strength of BioCryst Pharmaceuticals is 2 out of 10, which indicates that the financial strength of BioCryst Pharmaceuticals is poor. This is the debt and cash of BioCryst Pharmaceuticals over the past years:

debt and cash

Companies that have been consistently profitable over the long term offer less risk for investors who may want to purchase shares. Higher profit margins usually dictate a better investment compared to a company with lower profit margins. BioCryst Pharmaceuticals has been profitable 0 over the past 10 years. Over the past twelve months, the company had a revenue of $17.8 million and loss of $1.08 a share. Its operating margin is -981.12%, which ranks worse than 73% of the companies in Biotechnology industry. Overall, the profitability of BioCryst Pharmaceuticals is ranked 1 out of 10, which indicates poor profitability. This is the revenue and net income of BioCryst Pharmaceuticals over the past years:

Revnue and Net Income

Growth is probably one of the most important factors in the valuation of a company. GuruFocus’ research has found that growth is closely correlated with the long-term performance of a company’s stock. If a company’s business is growing, the company usually creates value for its shareholders, especially if the growth is profitable. Likewise, if a company’s revenue and earnings are declining, the value of the company will decrease. BioCryst Pharmaceuticals’s 3-year average revenue growth rate is worse than 73% of the companies in Biotechnology industry. BioCryst Pharmaceuticals’s 3-year average EBITDA growth rate is -14.4%, which ranks worse than 76% of the companies in Biotechnology industry.

Another way to look at the profitability of a company is to compare its return on invested capital and the weighted cost of capital. Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. We want to have the return on invested capital higher than the weighted cost of capital. For the past 12 months, BioCryst Pharmaceuticals’s return on invested capital is -295.87, and its cost of capital is 17.87. The historical ROIC vs WACC comparison of BioCryst Pharmaceuticals is shown below:


Overall, the stock of BioCryst Pharmaceuticals (NAS:BCRX, 30-year Financials) is believed to be significantly overvalued. The company’s financial condition is poor and its profitability is poor. Its growth ranks worse than 76% of the companies in Biotechnology industry. To learn more about BioCryst Pharmaceuticals stock, you can check out its 30-year Financials here.

To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.

Continue Reading


Regeneron Pharmaceuticals Inc. stock falls Friday, underperforms market




Shares of Regeneron Pharmaceuticals Inc.

shed 0.39% to $496.75 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index

rising 0.74% to 4,232.60 and the Dow Jones Industrial Average

rising 0.66% to 34,777.76. Regeneron Pharmaceuticals Inc. closed $167.89 short of its 52-week high ($664.64), which the company reached on July 20th.

The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson

rose 0.45% to $168.50, Novartis AG ADR

rose 0.70% to $87.96, and Amgen Inc.

rose 1.16% to $254.21. Trading volume (703,218) remained 165,258 below its 50-day average volume of 868,476.

Editor’s Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

Continue Reading